English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

This controlled comparison study evaluated objective and subjective cognitive function and their relationships with patient-reported symptoms (depression, fatigue, insomnia) in patients receiving tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and non-cancer controls. Patients with CML in chronic phase treated with the same oral TKI for ≥6 months ( n  = 90) and non-cancer controls ( n  = 87) completed a neurocognitive battery and self-report measures. Patients demonstrated worse overall neuropsychological performance  (p  = .05) and verbal memory ( p  = .02) compared to controls. Patients were not more likely to meet criteria for impaired cognitive performance compared to controls ( ps &gt;.26). Patients reported worse subjective global and domain-specific cognitive complaints and less satisfaction with cognitive function compared to controls ( p s &lt; .05). Patients also reported greater fatigue and insomnia symptoms ( p s &lt; .001). In both groups, greater fatigue, insomnia, and depressive symptoms were associated with worse subjective cognition ( p s &lt; .01). Longitudinal studies are needed to examine changes in cognitive function in patients before and during TKI treatment.

Cognition in patients treated with targeted therapy for chronic myeloid leukemia: a controlled comparison